The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.LA INVENCIÓN PROPORCIONA FORMULACIONES DE ANTICUERPOS ANTI-PDL1.